[Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
Nagashima
Kazuaki
K
Inagaki
Nobuya
N
D000284:Administration, Oral; D003510:Cyclohexanes / Q000008:administration & dosage* / Q000494:pharmacology; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005905:Glyburide / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D007231:Infant, Newborn; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D054086:KATP Channels / Q000737:chemistry / Q000235:genetics / Q000502:physiology; D009154:Mutation; D000077715:Nateglinide; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D013268:Stimulation, Chemical; D013453:Sulfonylurea Compounds / Q000008:administration & dosage* / Q000494:pharmacology
D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D054086:KATP Channels; D013453:Sulfonylurea Compounds; D000077715:Nateglinide; D010649:Phenylalanine; D005905:Glyburide